{
    "clinical_study": {
        "@rank": "45073", 
        "arm_group": [
            {
                "arm_group_label": "Genz-682452", 
                "arm_group_type": "Experimental", 
                "description": "This study will include three cohorts for doses of Genz-682452: Dose 1, Dose 2, Dose 3.  Each cohort will include 12 participants, 9 of whom will be administered Genz-682452 and 3 will be administered placebo."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo comparator taken by participants randomized to the placebo arm in each of the three cohorts.  Each cohort will include 12 participants, 9 of whom will be administered Genz-682452 and 3 will be administered placebo."
            }
        ], 
        "brief_summary": {
            "textblock": "To assess in healthy adult subjects:\n\n        -  The tolerability and safety of ascending repeated oral doses of Genz-682452.\n\n        -  The pharmacokinetic parameters of Genz-682452 after ascending repeated oral doses.\n\n        -  The pharmacodynamics of Genz-682452 after ascending repeated oral doses."
        }, 
        "brief_title": "A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Genz-682452 in Healthy Volunteers", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body weight between 50.0 and 95.0 kg, inclusive, if male and between 40.0 and 85.0 kg\n             inclusive, if female, body mass index between 18.0 and 30.0 kg/m^2, inclusive.\n\n          -  Certified as healthy by a comprehensive clinical assessment.\n\n        Exclusion Criteria:\n\n          -  Any history or presence of clinically relevant cardiovascular, pulmonary,\n             gastrointestinal, hepatic, renal, metabolic, hematological, neurological,\n             osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or\n             infectious disease, or signs of acute illness.\n\n          -  Frequent headaches and/or migraine, recurrent nausea and/or vomiting.\n\n          -  Blood donation, any volume, within 2 months before inclusion.\n\n          -  Symptomatic postural hypotension.\n\n          -  History or presence of drug or alcohol abuse.\n\n          -  Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen,\n             antihepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and\n             2 antibodies (anti-HIV1 and anti HIV2 Ab).\n\n          -  Positive result on urine drug screen."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710826", 
            "org_study_id": "GZFD00311", 
            "secondary_id": "TDR12768"
        }, 
        "intervention": [
            {
                "arm_group_label": "Genz-682452", 
                "description": "Capsules for oral administration.", 
                "intervention_name": "Genz-682452", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo capsules matching the Genz-682452 capsules.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-center, Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending 14-day Repeated Oral Doses of Genz-682452 in Healthy Male and Female Subjects", 
        "overall_official": {
            "affiliation": "Genzyme, a Sanofi Company", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Participants with Treatment-Emergent Adverse Events (TEAEs)", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1 through Day 14"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710826"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Maximum plasma concentration (Cmax), Plasma Concentration Observed Just Before Treatment Administration During Repeated Dosing (Ctrough), First time to reach Cmax (Tmax), Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval 0-23 hours (AUC0-24), Terminal Half-Life (t1/2z), Apparent Total Body Clearance of Genz-682452 at steady state (CLss/F), plasma 4 beta-hydroxycholesterol (4\u03b2-HC)", 
                "measure": "Pharmacokinetics as measure by plasma parameters", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 14"
            }, 
            {
                "measure": "Pharmacodynamics as measure by Plasma concentrations of Glucosylceramide (GL-1), Globotriaosylceramide (GL-3)  and GM3 ganglioside (GM3)", 
                "safety_issue": "No", 
                "time_frame": "Day 1, through Day 14"
            }, 
            {
                "measure": "Pharmacokinetics Urine parameter as measure by assessment of Genz-682452 in Urine, Ae0-t, fe0-t (Exploratory)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 14"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genzyme, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}